{
  "docId": "019dd923-622b-71dc-a6da-f68e9cf62b7a",
  "docSlug": "d8035db2dcbb",
  "documentTitle": "Bayer AG (BAYN)",
  "authorId": "04_Greenlight_Capital",
  "authorName": "David Einhorn",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2016-11-28 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 17,
  "pageCount": 48,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline visual to suggest extended market exclusivity for specific products.",
  "elementsJson": [
    "headline_text",
    "timeline_visual",
    "paragraph"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-f68e9cf62b7a/17",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-f68e9cf62b7a#slide-17",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "And not all patent cliffs are cliff-y.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f40-73bb-a610-cbacd9c43770",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Timeline from 2017 to 2029",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6ddca05-25cd-4aea-90f8-9726d405f10e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.76,
        "x": 0.12,
        "y": 0.5
      },
      "kind": "list",
      "text": "And not all patent cliffs are cliff-y. Eylea and the hemophilia drug Kogenate are biologics. Biologics are difficult to reproduce, so competition will be slow to market, and sales will fall off gently. And the manufacturing for its cancer drug Xofigo requires access to a nuclear facility, so not just anyone will be able to produce a generic. The Mirena IUD and Kogenate should have longer exclusivity as a result of something called Lifecycle Management.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9759ebe4-88f6-47af-90bb-bf050b27b590",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.26,
        "y": 0.26
      },
      "kind": "metric",
      "text": "Xofigo Cancer € 1B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "161b43af-d556-45b6-a513-b8ca8f88e38e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.08,
        "y": 0.26
      },
      "kind": "metric",
      "text": "Kogenate Hemophilia € 1.1B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6871b9d4-1088-439c-9e8e-3699e44c5c56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.56,
        "y": 0.26
      },
      "kind": "metric",
      "text": "Eylea Wet AMD € 2.5B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddc6ffa5-9ed0-4cb7-85dc-54a074e393a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.79,
        "y": 0.26
      },
      "kind": "metric",
      "text": "Mirena IUD € 1.2B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e055c748-997a-4c45-803e-a6a62be7b957",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.08
      },
      "kind": "title",
      "text": "Extended protection",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82b94bd2-ad4f-40e7-88d5-acdd0c98ca11",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "81f494e5-39ce-4405-a8cf-51158ec3fdba",
      "evidence": "The slide title 'Not all patent cliffs are cliff-y.' and the content that follows is a clear thesis archetype.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "7d75ddae-c34e-42d3-9847-ef8d155bade9",
      "evidence": "The slide explicitly addresses the counter-argument that patent expirations lead to immediate revenue loss.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "9db21285-546a-49b1-882e-f7933ceca20c",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "Highlighting Bayer's growth potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}